By VETTAPHARMA reporter – Derek Roche: AstraZeneca has completed its global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for lung cancer. Under the agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.
Zegfrovy is already approved in the US and China for the second-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. AstraZeneca plans to launch the medicine in the US in the fourth quarter of 2026 for this indication, while the medicine is already available to patients in China in the second-line setting.
The drug is also advancing toward potential first-line use. The US Food and Drug Administration has accepted a supplemental New Drug Application for Zegfrovy in the first-line setting, supported by positive results from the global WU-KONG28 Phase III trial in patients with first-line NSCLC carrying EGFR exon 20 insertion mutations. Zegfrovy has also been submitted to China’s Center for Drug Evaluation for first-line approval, with both the US FDA and China’s CDE granting Breakthrough Therapy Designation in this setting.
The transaction carries a substantial financial commitment. AstraZeneca will pay Dizal an upfront $600 million, followed by up to $900 million in additional development, regulatory and sales-related milestone payments. Dizal will also receive tiered royalties on global Zegfrovy sales. AstraZeneca stated that the transaction does not affect its 2026 financial guidance.
Zegfrovy is an irreversible EGFR inhibitor designed to target a broad spectrum of EGFR mutations while maintaining selectivity for wild-type EGFR. Its current approvals cover adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
The deal strengthens AstraZeneca’s lung cancer strategy by adding another EGFR-targeted medicine to a portfolio that includes Tagrisso, while extending its focus across different stages and molecular subtypes of NSCLC. The company is pursuing earlier intervention as well as new approaches for resistant and advanced disease, with the aim of matching treatments to patients who may benefit from them.
For patients with EGFR exon 20 insertion-positive NSCLC, the expansion of Zegfrovy into the first-line setting could potentially provide another targeted treatment option earlier in the disease course if regulatory approval is secured. The source highlights the substantial unmet need in this population, noting that real-world five-year overall survival can be as low as 8%.
Commercially, the agreement gives AstraZeneca worldwide rights to an already approved medicine while creating further potential through the pending first-line regulatory applications. With $600 million upfront and up to $900 million in milestones, plus tiered royalties, the transaction also establishes a significant financial commitment tied to Zegfrovy’s development, regulatory progress and sales.
Quick FAQs
1. What is EGFR exon 20 insertion-positive non-small cell lung cancer?
It is a molecularly defined form of NSCLC in which the cancer carries an EGFR exon 20 insertion mutation. The source identifies this population as having a significant unmet need, with real-world five-year overall survival reported as low as 8%.
2. What is the WU-KONG28 study?
WU-KONG28 is a global Phase III trial evaluating Zegfrovy in the first-line treatment of NSCLC with EGFR exon 20 insertion mutations. Positive results from the trial support the US supplemental New Drug Application for first-line use.
3. What is Zegfrovy (sunvozertinib)?
Zegfrovy is an oral irreversible EGFR inhibitor targeting a broad spectrum of EGFR mutations, with selectivity for wild-type EGFR.
4. What is the current approval status of Zegfrovy?
Zegfrovy is approved in the US and China for second-line treatment of adults with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations after progression on or following platinum-based chemotherapy.
5. Why is the FDA Breakthrough Therapy Designation important for Zegfrovy?
The FDA granted Zegfrovy Breakthrough Therapy Designation for the first-line setting, alongside a similar designation from China’s CDE, as the medicine advances toward potential first-line approval.
6. What are the financial terms of AstraZeneca’s Zegfrovy deal?
AstraZeneca will pay Dizal $600 million upfront, with up to $900 million in additional development, regulatory and sales-related milestones, plus tiered royalties on global Zegfrovy sales.
